Abstract
Insulin resistance has been associated with the development of type 2 diabetes, obesity, hypertension, dyslipidemia, atherosclerosis, and thus with increased cardiovascular morbidity and mortality. Insulin resistance precedes the onset of type 2 diabetes by many years. Targeting the pathophysiologic defects that characterize the onset of diabetes is more likely to achieve a durable glucose control and to delay disease progression. Incretins are gut-derived peptides that stimulate in a glucose-dependent mechanism insulin secretion and action. Glucose-like peptide 1 (GLP-1) analogues and dipeptidyl peptidase-4 (DPP-4) inhibitors both decrease fasting and postprandial glucose levels. In addition, GLP-1 analogues promote weight loss and exert a favorable effect on several cardiovascular risk factors. Data from human and experimental studies implicate that GLP-1 analogues and to a less extend DPP-4 inhibitors enhance insulin sensitivity. This review summarizes the current knowledge regarding the impact of GLP-1 analogues and DPP-4 inhibitors on insulin resistance.
Keywords: DPP-4 inhibitors, GLP-1 analogues, insulin resistance, type 2 diabetes.
Current Diabetes Reviews
Title:Incretin-based Therapies for Type 2 Diabetes Mellitus: Effects on Insulin Resistance
Volume: 9 Issue: 5
Author(s): Pinelopi Grigoropoulou, Ioanna Eleftheriadou, Christos Zoupas, Evanthia Diamanti-Kandarakis and Nicholas Tentolouris
Affiliation:
Keywords: DPP-4 inhibitors, GLP-1 analogues, insulin resistance, type 2 diabetes.
Abstract: Insulin resistance has been associated with the development of type 2 diabetes, obesity, hypertension, dyslipidemia, atherosclerosis, and thus with increased cardiovascular morbidity and mortality. Insulin resistance precedes the onset of type 2 diabetes by many years. Targeting the pathophysiologic defects that characterize the onset of diabetes is more likely to achieve a durable glucose control and to delay disease progression. Incretins are gut-derived peptides that stimulate in a glucose-dependent mechanism insulin secretion and action. Glucose-like peptide 1 (GLP-1) analogues and dipeptidyl peptidase-4 (DPP-4) inhibitors both decrease fasting and postprandial glucose levels. In addition, GLP-1 analogues promote weight loss and exert a favorable effect on several cardiovascular risk factors. Data from human and experimental studies implicate that GLP-1 analogues and to a less extend DPP-4 inhibitors enhance insulin sensitivity. This review summarizes the current knowledge regarding the impact of GLP-1 analogues and DPP-4 inhibitors on insulin resistance.
Export Options
About this article
Cite this article as:
Grigoropoulou Pinelopi, Eleftheriadou Ioanna, Zoupas Christos, Diamanti-Kandarakis Evanthia and Tentolouris Nicholas, Incretin-based Therapies for Type 2 Diabetes Mellitus: Effects on Insulin Resistance, Current Diabetes Reviews 2013; 9 (5) . https://dx.doi.org/10.2174/15733998113099990070
DOI https://dx.doi.org/10.2174/15733998113099990070 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Development and Validation of a New Method to Quantify Pilocarpine in Tablets by HPLC-DAD
Current Pharmaceutical Analysis Natural Products Towards the Discovery of Potential Future Antithrombotic Drugs
Current Pharmaceutical Design New Biochemical Markers in Acute Coronary Syndromes
Current Medicinal Chemistry Inflammation in Ischemic Stroke Subtypes
Current Pharmaceutical Design Editorial: Leptin and the Cardiovascular System - A Target for Therapeutic Interventions
Current Pharmaceutical Design Detection of Secretion Retention in the Ventilated Patient
Current Respiratory Medicine Reviews Combination of Phytosterols and Omega-3 Fatty Acids: A Potential Strategy to Promote Cardiovascular Health
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Development and Clinical use of Prasugrel and Ticagrelor
Current Pharmaceutical Design Genetics of Vesicoureteral Reflux
Current Genomics Sedation in PACU: Indications, Monitoring, Complications
Current Drug Targets Cortisol Regulation in the Metabolic Syndrome. A Novel Therapeutic Approach
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Enhancing Endothelial Progenitor Cell Function Through Selective Estrogen Receptor Modulation: A Potential Approach to Cardiovascular Risk Reduction
Cardiovascular & Hematological Agents in Medicinal Chemistry Oxidative Stress: Meeting Multiple Targets in Pathogenesis of Diabetic Nephropathy
Current Drug Targets Post-locoregional Therapy MRI Evaluation of Malignant Liver Lesions
Current Cancer Therapy Reviews Apoptosis Modulated by Oxidative Stress and Inflammation During Obstructive Nephropathy
Inflammation & Allergy - Drug Targets (Discontinued) Surgical Ventricular Restoration: An Operation to Reverse Remodeling - Clinical Application (Part II) (Supplementry Table)
Current Cardiology Reviews QT Interval Monitoring and Drugs Management During COVID-19 Pandemic
Current Reviews in Clinical and Experimental Pharmacology Hepatic Diseases Related to Triglyceride Metabolism
Mini-Reviews in Medicinal Chemistry The Effect of Different Grades of PLGA on Characteristics of Microspheres Encapsulated with Cyclosporine A
Current Drug Delivery Treating Heart Failure with Preserved Ejection Fraction Related to Arterial Stiffness. Can we Kill Two Birds With One Stone?
Current Vascular Pharmacology